, respectively. Factor Xa completely blocked APC-catalyzed cleavage at Arg 506 in normal factor Va (1 nM) with a half-maximal effect (K1 ⁄2Xa ) at 1.9 nM factor Xa. Expression of cofactor activity of factor Va in prothrombin activation required much lower factor Xa concentrations (K1 ⁄2Xa ‫؍‬ 0.08 nM). When the ability of factor Xa to protect factor Va from inactivation by APC was determined at low factor Va concentrations during prothrombin activation much lower amounts of factor Xa were required (K1 ⁄2Xa ‫؍‬ 0.03 nM). This indicates 1) that factor Va is optimally protected from inactivation by APC by incorporation into the prothrombinase complex during ongoing prothrombin activation, and 2) that the formation of a catalytically active prothrombinase complex and protection of factor Va from inactivation by APC likely involves the same interaction of factor Xa with factor Va. In accordance with the proposed mechanisms of action of protein S and factor Xa, we observed that the large differences between the rates of APC-catalyzed inactivation of normal factor Va and factor Va R506Q were almost annihilated in the presence of factor Xa and protein S. This observation may explain why, in the absence of other risk factors, APC resistance only results in a weak prothrombotic condition.
, which was isolated from the plasma of a homozygous APC-resistant patient and which lacks the Arg 506 cleavage site, was also stimulated by protein S but was not affected by factor Xa. This confirms that the target sites of protein S and factor Xa involve Arg 306 and Arg
506
, respectively. Factor Xa completely blocked APC-catalyzed cleavage at Arg 506 in normal factor Va (1 nM) with a half-maximal effect (K1 ⁄2Xa ) at 1.9 nM factor Xa. Expression of cofactor activity of factor Va in prothrombin activation required much lower factor Xa concentrations (K1 ⁄2Xa ‫؍‬ 0.08 nM). When the ability of factor Xa to protect factor Va from inactivation by APC was determined at low factor Va concentrations during prothrombin activation much lower amounts of factor Xa were required (K1 ⁄2Xa ‫؍‬ 0.03 nM). This indicates 1) that factor Va is optimally protected from inactivation by APC by incorporation into the prothrombinase complex during ongoing prothrombin activation, and 2) that the formation of a catalytically active prothrombinase complex and protection of factor Va from inactivation by APC likely involves the same interaction of factor Xa with factor Va. In accordance with the proposed mechanisms of action of protein S and factor Xa, we observed that the large differences between the rates of APC-catalyzed inactivation of normal factor Va and factor Va R506Q were almost annihilated in the presence of factor Xa and protein S. This observation may explain why, in the absence of other risk factors, APC resistance only results in a weak prothrombotic condition.
Activated protein C (APC)
1 plays an important role in the down-regulation of thrombin formation (1) . The anticoagulant action of APC is associated with its ability to degrade the activated cofactors of the coagulation cascade, factors Va (2, 3) and VIIIa (4, 5) , by limited proteolysis. The mechanism of proteolytic inactivation of factor Va by APC is rather well documented. Human factor Va loses its cofactor activity in prothrombin activation after peptide bond cleavages in the heavy chain (6) . Sequential cleavage at Arg 506 and Arg 306 of the heavy chain appears to be the major pathway of APC-catalyzed factor Va inactivation (6 -8) .
Optimal expression of anticoagulant activity of APC requires the presence of negatively charged phospholipids (3, 9, 10) and the protein cofactor, protein S (10 -12) . The mechanism of action of protein S in factor Va inactivation is as yet not fully understood. In reaction systems with purified coagulation factors, protein S is a weak stimulator of APC-catalyzed factor Va inactivation (10, 12) . It has been suggested (12) that under physiological conditions protein S may act by annihilating the ability of factor Xa to protect factor Va from inactivation by APC (3, 9, 13, 14) .
The importance of protein C and protein S in the regulation of hemostatic plug formation is demonstrated by the association between thrombosis and protein C or protein S deficiency (15) (16) (17) . Recently, it has been reported (18 -21) that a hereditary defect that results in a poor anticoagulant response to APC (APC resistance) also is a basis for familial thrombophilia. APC resistance is associated with a single point mutation in the factor V gene that results in the replacement of Arg 506 by Gln (22) (23) (24) (25) . This replacement affects the peptide bond in factor Va that has to be cleaved by APC in order to obtain a rapid loss of factor Va cofactor activity (6 -8) .
In the present study we have determined the effects of protein S and factor Xa on apparent second order rate constants for APC-catalyzed inactivation of normal factor Va and of factor Va that was purified from the plasma of a patient who is homozygous for the mutation Arg 506 3 Gln. The loss of functional activity of factor Va was correlated with the effects of protein S and factor Xa on the cleavage of APC-susceptible peptide bonds in the heavy chain of factor Va by immunoblot analysis.
EXPERIMENTAL PROCEDURES
Materials-Hepes, Tris, bovine serum albumin, soybean trypsin inhibitor (type IS), and Russell's viper venom were purchased from Sigma. DOPC and DOPS were obtained from Avanti Polar Lipids, Pelham, AL. The micro-BCA protein assay reagent kit was obtained from Pierce. The chromogenic substrates S2238 and S2366 were supplied by Chromogenix, Mölndal, Sweden. 1,5-DNS-GGACK was obtained from Calbiochem and p-NPGB was from Nutritional Biochemicals. FPLC equipment and column materials used for protein purification were purchased from Pharmacia, Uppsala, Sweden. Immobilon-P membranes were obtained from Millipore, Bedford, MA.
Proteins-Human coagulation factors were isolated from fresh frozen plasma. Human prothrombin and factor X were purified according to DiScipio et al. (26) . Human thrombin was isolated from prothrombin activation mixtures as described by Pletcher and Nelsestuen (27) . Human factor Xa was obtained from purified factor X after activation with RVV-X and isolation from the activation mixture by affinity chromatography on soybean trypsin inhibitor-Sepharose (28). 1,5-DNS-GGACK-factor Xa was obtained by incubating 4 M factor Xa with 10 M 1,5-DNS-GGACK till inhibition was complete. Excess 1,5-DNS-GGACK was removed on a PD-10 column (Pharmacia). RVV-X was purified from Russel's viper venom according to Schiffman et al. (29) . Human protein C was prepared and activated as described by Gruber et al. (30) . Protein S was obtained from Enzyme Research Laboratories Inc. (Swansea, United Kingdom). Human factor V, factor V R506Q , factor Va, and factor Va R506Q were purified as described previously (8) . Protein Concentrations-Protein concentrations were determined with the micro-BCA protein assay (31) . Molar thrombin and factor Xa concentrations were determined by active site titration with p-NPGB (32, 33) . The concentration 1,5-DNS-GGACK-factor Xa was determined with the micro-BCA protein assay calibrated with active site-titrated factor Xa. Prothrombin concentrations were determined after complete activation of prothrombin with Echis carinatus venom and quantitation of thrombin with p-NPGB. The APC concentration was determined with S2366 using kinetic parameters reported by Sala et al. (34) . Protein S concentrations were calculated from the A 280 using a A 280 1% of 9.5 and M r ϭ 70,000 for protein S (35) . Factor Va was quantitated as described below.
Phospholipid Vesicle Preparations-Small unilamellar phospholipid vesicles were prepared as described before (36) . Phospholipid concentrations were determined by phosphate analysis (37) .
Gel Electrophoretic and Immunoblot Analysis-The purity of protein preparations was analyzed by SDS-PAGE according to Laemmli (38) and staining with Coomassie Brilliant Blue R-250. The inactivation patterns of factor Va were analyzed after SDS-PAGE on 8% acrylamide slab gels, electrophoretic transfer of proteins from the gel to Immobilon-P membranes, and visualization of heavy chain fragments with a rabbit polyclonal antibody directed against the heavy chain of factor Va and goat anti-rabbit IgG conjugated with alkaline phosphatase as described by Blake et al. (39) .
Factor Va Assay-Cofactor activity of factor Va was quantitated by determining the rate of factor Xa-catalyzed prothrombin activation in reaction mixtures that contained a limiting amount of factor Va, 5 nM factor Xa, 50 M phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol), and 0.5 M prothrombin (40) . Rates of prothrombin activation were determined with S2238 (41) . The molar factor Va concentration in the assay mixture was calculated from the rate of prothrombin activation using a turnover number of 6000 mol of prothrombin activated/min/mol of factor Xa-Va complex (42 
8).
In some experiments (factor Va inactivation in the presence of high factor Xa concentrations), there was a slow loss of factor Va cofactor activity in the absence of APC. In these cases the rate constant for the loss of cofactor activity in the absence of APC was determined in a separate experiment and added to kЈ 306 .
RESULTS

Peptide Bonds in the Heavy Chain of Human Factor Va That
Can Be Cleaved by APC-Recently it was reported (6) that APC is able to cleave three peptide bonds in the heavy chain of human factor Va, which are located at Arg , respectively. Fig. 1 is a schematic representation of the heavy chain of factor Va in which we have indicated the peptide bonds that can be cleaved by APC and the molecular weights of possible cleavage products. In this paper we will refer to the rate constants associated with the indicated peptide bond cleavages as k 306 , k 506 , and k 679 , respectively.
Effect of Protein S on APC-catalyzed Inactivation of Membrane-bound Factor
Va-Inactivation of membrane-bound factor Va by APC occurred via a biphasic reaction that consisted of a rapid phase, which resulted in the formation of a reaction intermediate with partial cofactor activity (40%) that was fully inactivated during the subsequent slow phase ( Fig. 2; cf. Ref. was considerably accelerated and full loss of cofactor activity was achieved after a much shorter time interval than without protein S (Fig. 2) . This indicates that protein S preferentially accelerates the slow phase of factor Va inactivation, i.e. promotes APC-catalyzed cleavage at Arg . This indicates that protein S increases the rate of APC-catalyzed cleavage at Arg 306 at least 18-fold. The proposed mode of action of protein S was confirmed by immunoblot analysis of heavy chain degradation during factor Va inactivation (Fig. 3) . When factor Va was inactivated by APC in the absence of protein S, there was considerable accumulation of a transient reaction product with M r ϭ 75,000 and formation of a M r ϭ 26,000/28,000 doublet, which are generated as the result of rapid cleavage at Arg 506 (Fig. 3A) . The reaction intermediate with M r ϭ 75,000 was slowly converted into products with M r ϭ 45,000 and M r ϭ 30,000, which is indicative for cleavage at Arg 306 . The reaction product with M r ϭ 30,000 was hardly visible on the gel since it stains poorly with our polyclonal antibody against the heavy chain.
Immunoblot analysis of a time course of factor Va inactivation in the presence of protein S showed much less accumulation of the M r ϭ 75,000 intermediate (Fig. 3B) . The fact that formation of the fragments with M r ϭ 26,000/28,000 occurred at the same rate as without protein S and that the fragments with M r ϭ 60,000/62,000 and M r ϭ 45,000 were already visible at early time points (Ͻ0.5 min) supports our conclusion that protein S does not affect cleavage at (3, 9, 13, 14) . We also observed that factor Xa strongly inhibited APCcatalyzed inactivation of membrane-bound factor Va (Fig. 4) . The rate constant calculated from the initial phase of the inactivation time course in the presence of factor Xa was 2.3 ϫ . Since this rate constant is almost equal to the k 306 determined in the absence of factor Xa, we propose that factor Xa blocks APC-catalyzed cleavage at Arg 506 without affecting the cleavage at Arg 306 . The presence of the active site of factor Xa was not needed for its protective effect since a factor Xa derivative, in which the active site had been blocked with the chloromethylketone 1,5-DNS-GGACK, was equally effective in inhibiting APC-dependent inactivation (Fig. 4, solid squares) .
The selective inhibition of the cleavage at Arg 506 was confirmed by immunoblot analysis of APC-catalyzed inactivation of membrane-bound factor Va in the absence (Fig. 5A) and presence (Fig. 5B ) of factor Xa. Comparison of the immunoblots shows that factor Xa prevented formation of the M r ϭ 75,000 heavy chain degradation product, which is indicative for inhibition of the cleavage at Arg 506 and which shows that APC converts factor Va directly, but slowly, into products with M r ϭ 62,000/60,000 and 45,000 by cleavage at Arg 306 . , it is to be expected that protein S will considerably enhance the inactivation of this abnormal factor Va variant and that factor Xa will have no effect on APC-catalyzed inactivation of factor Va ) and that the inactivation of factor Va R506Q was not affected by factor Xa.
Effects of Protein S and Factor Xa on APC-catalyzed Inacti-
In Table I we have summarized the rate constants for APCcatalyzed cleavage at Arg 506 and Arg 306 of the heavy chain of membrane-bound factor Va and factor Va R506Q that were determined in the absence and presence of protein S or factor Xa.
Concentration Dependence of the Effects of Protein S and Factor Xa on APC-catalyzed Inactivation of Membrane-bound
Factor Va-We have also examined the enhancement of APCcatalyzed factor Va inactivation as a function of the protein S concentration (Fig. 7A) . Time courses of factor Va inactivation by APC were determined at varying concentrations of protein S (cf. We have also determined the ability of factor Xa to protect factor Va from APC inactivation at varying factor Xa concentrations (Fig. 7B) . Factor Xa could completely block cleavage at Arg 506 without having an effect on the slow phase of factor Va inactivation (k 306 ). Half-maximal protection of cleavage at Arg 506 was observed at 1.9 nM factor Xa. It appeared that protein S and factor Xa can exert their effects on APC-catalyzed factor Va inactivation independent of each other. At a concentration of factor Xa that completely blocked cleavage at Arg 506 (20 nM), protein S was still able to accelerate factor Va inactivation 12-fold (Fig. 8) . The fact that the time course of inactivation determined in the presence of factor Xa and protein S significantly differs from that obtained in the presence of protein S alone indicates that the factor Xa protection of cleavage at Arg 506 was not annihilated by protein S.
Collectively these data support our conclusion that the stimulatory effect of protein S and the protective effect of factor Xa are associated with the different steps in the pathway of APCcatalyzed factor Va inactivation, i.e. are confined to the peptide bond cleavages at Arg 506 and Arg
306
, respectively.
Inactivation of Factor Va and Factor Va
R506Q by APC in the Presence of Both Factor Xa and Protein S-On the basis of the proposed sites of action of protein S and factor Xa, one would predict that the profound differences between the inactivation rates of factor Va and factor Va R506Q by APC will disappear in reaction systems that contain both protein S and factor Xa. The experiment presented in Fig. 9 shows that this indeed occurs. In the absence of protein S and factor Xa, the rates of inactivation of factor Va and factor Va R506Q by APC differed about 15-fold. The rate difference was almost completely annihilated in inactivation mixtures that contained protein S and factor Xa. This phenomenon is explained by the fact that factor Xa prevents APC-catalyzed cleavage at the site (Arg 506 ) that distinguishes normal factor Va from factor Va R506Q , and that protein S stimulates cleavage Arg 306 in both normal factor Va and factor Va R506Q .
Protection of Factor Va against APC Inactivation by Incorporation in the Prothrombinase
Complex-Protection of factor Va from cleavage by APC appears to require much higher factor Xa concentrations (K1 ⁄2Xa ϭ 1.9 nM) than needed for the expression of cofactor activity of factor Va in prothrombin activation (K1 ⁄2Xa ϭ 0.05-0.10 nM; cf. Refs. 8 and 36). It should be emphasized, however, that expression of factor Va cofactor activity by factor Xa is determined 1) in the presence of prothrombin, a protein that may promote factor Xa-Va complex formation (cf. Ref. 44) and 2) at factor Va concentrations (0.005-0.05 nM) that are several orders of magnitude lower than the factor Va concentrations in experiments in which inactivation by APC is studied.
Therefore, we have determined in the same experiment the amounts of factor Xa required to protect factor Va from APC cleavage and to express the cofactor activity of factor Va in prothrombin activation (Fig. 10) . Under these conditions (low concentration of factor Va and prothrombin present), similar amounts of factor Xa were required to protect factor Va from inactivation by APC and to express factor Va cofactor activity in prothrombin activation (K1 ⁄2Xa ϭ 0.03 nM for protection, K1 ⁄2Xa ϭ 0.08 nM for the expression of cofactor activity). These data indicate that factor Va is optimally protected from inactivation by APC when it is incorporated into the prothrombinase complex during ongoing catalysis and that complex formation between factor Xa and factor Va at the same time expresses the cofactor activity of factor Va and protects it from inactivation by APC. DISCUSSION Recently it has been reported that APC-catalyzed inactivation of factor Va proceeds via a biphasic reaction (6 -8) . The first step of the inactivation process is a rapid cleavage at Arg 506 in the heavy chain domain of factor Va that results in the formation of a reaction intermediate that exhibits partial cofactor activity in prothrombin activation. This reaction intermediate is subsequently fully inactivated by slow cleavage at Arg
306
. Here we report that protein S stimulates the inactiva- tion of membrane-bound factor Va 20-fold by specific acceleration of the cleavage at Arg 306 and that factor Xa protects factor Va from inactivation by APC by blocking the cleavage site at Arg 506 . However, factor Xa does not completely inhibit factor Va inactivation by APC. At saturating factor Xa concentrations, factor Va inactivation still proceeds with a slow rate that is associated with APC-catalyzed cleavage at Arg 306 . This means that the latter cleavage is apparently not affected by factor Xa.
These conclusions are supported by immunoblot analysis and by experiments with factor Va R506Q obtained from a homozygous APC-resistant patient. Immunoblots of time courses of inactivation of membrane-bound factor Va by APC, in which the heavy chain and its degradation products were visualized with a polyclonal antibody directed against the heavy chain, showed transient generation of a reaction product with M r ϭ 75,000 which is formed after rapid cleavage of the peptide bond at Arg 506 by APC (Fig. 3A) . With protein S present there is much less accumulation of the M r ϭ 75,000 fragment and increased formation of products with M r of 60,000/62,000, and 45,000 (Fig. 3B ). This is indicative for a protein S-dependent increase of the rate of cleavage at Arg 306 , which either results in increased direct factor Va inactivation or in accelerated processing of the M r ϭ 75,000 intermediate.
In the presence of factor Xa, there is also no formation of the M r ϭ 75,000 reaction intermediate (Fig. 5B) by Gln (22) (23) (24) (25) . In line with the proposed effects of protein S and factor Xa on APC-catalyzed peptide bond cleavages in the heavy chain of factor Va, we observed that protein S drastically stimulates inactivation of factor Va R506Q (Fig. 6 ), which has been reported to be primarily associated with cleavage at Arg 306 (7, 8) . We further show that factor Xa does not protect factor Va R506Q from inactivation by APC. This observation is explained by the fact that factor Va R506Q lacks Arg 506 , which is the target site for factor Xa.
It is the first time that a profound effect is reported for protein S in a reaction system with purified coagulation factors. In earlier publications (10, 12), modest effects were described for protein S. The reason for this apparent discrepancy is that in the earlier studies the effect of protein S was determined on initial rates of APC-catalyzed factor Va inactivation that is a phase of the reaction that is primarily associated with cleavage at Arg 506 and which, according to our data, is hardly affected by protein S. Here we show that protein S actually acts at the slower step of the inactivation process, that is the cleavage of the peptide bond at Arg ) into a product with no detectable cofactor activity. Given the known clinical consequences of protein S deficiencies, it is likely that the above described contribution of protein S to factor Va inactivation is of prime physiological importance.
Titration experiments at low APC and factor Va concentrations on 25 M DOPS/DOPC phospholipid vesicles show that protein S stimulates APC-catalyzed inactivation of factor Va with a K1 ⁄2 of 200 nM and that protection by factor Xa is characterized by a K1 ⁄2Xa of 1.9 nM. We have further shown that protein S and factor Xa can exert their effects on APC-catalyzed factor Va inactivation independent of each other. At a concentration of factor Xa that completely blocks cleavage at Arg 506 , protein S was still able to accelerate factor Va inactivation 12-fold. These data support our conclusion that the stimulatory effect of protein S and the protective effect of factor Xa on inactivation of factor Va by APC result from different interactions with factor Va and are confined to steps that involve the peptide bond cleavages at Arg 306 and Arg
506
, respectively. In terms of physiological relevance for regulation of factor Va activity, factor Xa actually has two (procoagulant) functions: 1) factor Xa protects factor Va from inactivation by APC and 2) factor Xa brings the cofactor activity of factor Va to expression by formation of the prothrombin-activating complex. It appeared that much higher concentrations of factor Xa were required for protection of factor Va from inactivation by APC (K1 ⁄2Xa ϭ 1.9 nM) than for incorporation of factor Va into a catalytically active prothrombinase complex (K1 ⁄2Xa ϭ 0.08 nM). However, prothrombinase complex formation is usually determined at low factor Va concentrations in reaction mixtures that contain prothrombin as additional component. We observed that much lower amounts of factor Xa (K1 ⁄2Xa ϭ 0.03 nM) were required to protect factor Va from inactivation by APC when it was incorporated into a prothrombinase complex that was catalyzing prothrombin activation. These data demonstrate: 1) that factor Va is most effectively protected from inactivation by APC when incorporated into the prothrombinase complex during ongoing prothrombin activation and 2) that protection of factor Va from APC cleavage and prothrombinase complex formation likely involve the same interaction of factor Xa with factor Va.
Recently, it was recognized that APC resistance alone is only a mild risk factor for thrombosis (46 -48) . Considering the large differences in inactivation rates of factor Va and factor Va R506Q by APC, this is a somewhat puzzling observation. In accordance with the proposed effects of protein S and factor Xa, we observed that the large differences in the rates of APC-catalyzed inactivation of factor Va and Va R506Q were almost annihilated when factor Va and factor Va R506Q were inactivated by APC in the presence of factor Xa and protein S (Fig. 9) . Since it is likely that in vivo regulation of factor Va activity by APC occurs in the presence of protein S and factor Xa, our observations may explain why in the absence of other genetic or environmental risk factors APC resistance only results in a relatively weak prothrombotic condition.
